1221443-94-2
1221443-94-2
Chemical Structure
A-1165442
- CAS No.: 1221443-94-2
- Formula:C22H20ClF2N3O2
- Molecular Weight:431.86
IUPAC Name: (R)-1-(7-chloro-2,2-bis(fluoromethyl)chroman-4-yl)-3-(3-methylisoquinolin-5-yl)urea
InChIKey: VJJGAJAUECQWSZ-LJQANCHMSA-N
SMILES: O=C(NC1=CC=CC2=C1C=C(C)N=C2)N[C@H]3C4=CC=C(Cl)C=C4OC(CF)(CF)C3
Biological Activity: A-1165442 is a potent, competitive and orally available TRPV1 antagonist with an IC50 of 9 nM for human TRPV1.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
A-1165442 | 99.94% | A-1165442 is a potent, competitive and orally available TRPV1 antagonist with an IC50 of 9 nM for human TRPV1. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GRC-6211 | GRC-6211 is an orally active and selective TRPV1 antagonist. GRC-6211 exhibits anti-inflammation effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ABT-102 | 98.50% | ABT-102 is a potent and highly selective Vanilloid Receptor (TRPV1) receptor antagonist. ABT-102 potently and reversibly increases heat pain thresholds and reduced painfulness of suprathreshold oral/cutaneous heat. ABT-102 reduces nociceptive responses of animals in models of inflammatory, bone cancer, postoperative, and osteoarthritic pain. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(S)-ABT-102 | 99.64% | (S)-ABT-102 is a TRPV1 Antagonist, with an IC50 of 123 nM. (S)-ABT-102 has analgesic activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lenvatinib | 99.75% | Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
A-425619 | 99.96% | A-425619 is an orally active and selective transient receptor potential type V1 (TRPV1) antagonist. A-425619 blocks Capsaicin (HY-10448)- and N-arachidonoyl-dopamine (NADA)-induced Ca2+ influx in dorsal root ganglia and trigeminal ganglia. A-425619 relieves pathophysiological pain associated with inflammation and tissue injury in rats. A-425619 can be used for the study of pain related to inflammation and tissue injury. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
A778317 | A778317 is a TRPV1 antagonists. A778317 can block changes in intracellular calcium levels mediated by TRPV1 receptors, with a pIC50 value of 8.31. A-778317 can also block the activation of natural rat TRPV1 receptors in dorsal root ganglion neurons by capsaicin and acid. |
|||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PQ401 | 99.85% | PQ401 is a potent inhibitor of IGF-IR signaling. PQ401 inhibits IGF-I-stimulated IGF-IR autophosphorylation with an IC50 of 12.0 μM in a series of studies in MCF-7 cells. PQ401 is effective at inhibiting IGF-I-stimulated growth of MCF-7 cells (IC50, 6 μM). PQ401 is a potential agent for breast and other IGF-I-sensitive cancers. PQ401 induces caspase-mediated apoptosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sirtuin-IN-1 | Sirtuin-IN-1 (Compound 18) is a SIRT1/2 inhibitor (IC50s: 6.2 μM and 4.2μM for SIRT1 and SIRT2, respectively). Sirtuin-IN-1 induces G1 cell cycle arrest. Sirtuin-IN-1 exhibits potent anti-cancer activity against glioma. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
STING-IN-11 | 98.65% | STING-IN-11 (Compound 42) is an orally active STING inhibitor with an IC50 of 37.8 nM. STING-IN-11 can block the palmitoylation of the STING protein and STING downstream signaling, and inhibit STING-mediated inflammation. STING-IN-11 has good in vivo safety and can be used for the research of STING-related inflammatory and autoimmune diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PZL-A | 99.72% | PZL-A is a activator of mitochondrial DNA (mtDNA) synthesis. PZL-A restores wild-type-like activity to mutant forms of polymerase γ (POLγ) with AC50 s of 160 and 20 nM for A467T and G848S. PZL-A activates mtDNA synthesis in cells, enhancing biogenesis of the oxidative phosphorylation machinery and cellular respiration. PZL-A is promising for relieving POLG disease and other severe conditions linked to depletion of mtDNA. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
